Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Home page for Eli Lilly and Company in India.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Jul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks. Listen to ...
Since its inception in India in 1993, Eli Lilly and Company (India) Pvt. Ltd. has been committed to developing and marketing pharmaceutical products to treat diabetes, gastric cancer, lung cancer, breast cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency.
Mar 31, 2024 · Lilly at a Glance. A heritage 148 years strong: company founded on May 10, 1876. Headquarters located in Indianapolis, Indiana, U.S.A. More than 44,000 employees worldwide. Approximately 10,000 employees engaged in research and development. Clinical research conducted in more than 55 countries.
Jul 2, 2024 · INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology. 1, 2 Once-monthly Kisunla is the first and only ...
3 days ago · Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory bowel disease (IBD) drugs and expanding its footprint in ...
